Study explores potential of HDACs to treat autoimmune diseases

10/7/2007 | Yahoo!

A new class of cancer drugs known as histone deacetylases inhibitors, or HDACs, may also treat autoimmune diseases such as rheumatoid arthritis and Crohn's disease, scientists report. In testing Merck's skin cancer treatment Zolinza, the researchers found that the drug enhanced the production of cells that regulate the immune system in mice, preventing inflammatory bowel disease and the rejection of heart transplants.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care